-

Denise Vitola Joins Bayer Communications Team

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer today announced Denise Vitola is joining the Bayer Communications Team as Vice President of Brand Integration, PR, Social and Influencer for Consumer Health. In this role, Vitola will be responsible for leading strategy for integrated brand PR, social media and influencer marketing for all Consumer Health U.S. brands.

For the last two years, Vitola has played an integral role as a consultant leading internal communications and brand PR for Bayer Consumer Health North America, including spearheading the advancement of influencer marketing and organic social for Consumer Health North America and launching new integrated campaigns for Midol®, Bayer® Aspirin, AleveX™, One-A-Day®, Claritin® and Alka-Seltzer®.

Vitola will report to Beth Roden, SVP and Head of Communications – Bayer U.S. and Head of Communications, Consumer Health North America. Denise will also be a member of the U.S. Corporate Communications Leadership Team, driving reputation, digital excellence and integrated communications.

“Over the last two years, Denise has elevated and brought new relevance to Bayer Consumer Health North America’s largest brands that have been around for decades through integrated marketing, including impactful influencer and social media programs, to truly deliver exceptional results,” Roden said. “We are thrilled she is now officially a member of the Bayer Communications team and will continue to drive our successful integrated communications that has been an essential part of reaching our consumers and driving awareness of our brands.”

Vitola has over a decade and a half of award-winning, branding and integrated marketing experience. She has a broad background working on clients in consumer, health, tech and financial services. Prior to working with Bayer Consumer Health North America, Vitola helped drive innovation and strategy through integrated, social and holistic marketing campaigns for global brands. Earlier this year, Vitola was named a 2021 PRNews Top Woman in PR.

About Bayer

Bayer is a global enterprise with core competencies in the life science fields of health care and nutrition. Its products and services are designed to help people and planet thrive by supporting efforts to master the major challenges presented by a growing and aging global population. Bayer is committed to drive sustainable development and generate a positive impact with its businesses. At the same time, the Group aims to increase its earning power and create value through innovation and growth. The Bayer brand stands for trust, reliability and quality throughout the world. In fiscal 2020, the Group employed around 100,000 people and had sales of 41.4 billion euros. R&D expenses before special items amounted to 4.9 billion euros. For more information, go to www.bayer.com.

Social Media Channels

- Facebook: BayerUnitedStates
- Twitter: BayerUS
- Instagram: BayerUS
- YouTube: BayerUS

Bayer® and the Bayer Cross® are registered trademarks of Bayer.

Contacts

Danielle Goonan
danielle.goonan@bayer.com

Bayer


Release Versions

Contacts

Danielle Goonan
danielle.goonan@bayer.com

More News From Bayer

ASCO 2026: Bayer to Present New Data Across Oncology Portfolio

WHIPPANY, N.J.--(BUSINESS WIRE)--ASCO 2026: Bayer to Present New Data Across Oncology Portfolio...

Bayer’s KERENDIA® (finerenone) Granted Priority Review of Supplemental New Drug Application by U.S. FDA for Treatment of Adults with Type 1 Diabetes and Chronic Kidney Disease

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer Summary Bayer announced today that the U.S. Food and Drug Administration (FDA) accepted its supplemental New Drug Application (sNDA) and granted Priority Review designation for KERENDIA® (finerenone), which is being investigated for the treatment of adults with type 1 diabetes (T1D) and chronic kidney disease (CKD). Key Facts The sNDA was supported by the Phase III FINE-ONE trial, which showed KERENDIA significantly reduced urine albumin-to-creatinine rati...

Bayer Granted Priority Review by U.S. FDA for Asundexian in Patients After a Non-Cardioembolic Ischemic Stroke or Transient Ischemic Attack

WHIPPANY, N.J.--(BUSINESS WIRE)--Bayer: WHAT’S HAPPENING Bayer today announced that the U.S. Food and Drug Administration (FDA) has accepted the company’s New Drug Application (NDA) and granted Priority Review designation for its investigational oral Factor XIa (FXIa) inhibitor, asundexian, for the prevention of secondary stroke in patients following a non-cardioembolic ischemic stroke or transient ischemic attack (TIA). The NDA is based on positive results from the global, pivotal Phase III OC...
Back to Newsroom